Smart Peptide Defense Web In Situ Connects for Continuous Interception of IgE against Allergic Rhinitis

Abstract

Allergic rhinitis (AR) is a chronic inflammatory reaction by immunoglobulin E (IgE) mediators after individual contact with allergens. It affects 10–40% of the world’s population and reduces the quality of life. Long-term symptoms of rhinitis can cause inflammation to spread and trigger asthma, which can harm human health. Herein, we develop a Smart PeptIde defeNse (SPIN) web technique, which in situ constructs a peptide web, trapping IgE against AR. Two candidate SPINs, SPIN-1 and SPIN-2, are designed with different IgE-binding sequences. The SPIN-1 or SPIN-2 is able to bind to IgE and transform from nanoparticles into entangled nanofibers. In turn, the web of SPIN-1 or SPIN-2 acts as a long-term trap of IgE to prevent the IgE from binding to mast cells. SPIN-1 or SPIN-2 (10 mg/kg) is able to treat AR model Balb/c mice with high efficiency and reduced symptoms of rhinitis and inflammatory factors, even better than a first-line clinical drug, cetirizine (10 mg/kg). For example, the amount of IL-4 released in the AR group (185.5 ± 6.8 pg/mL) is significantly reduced after the treatment with SPIN-1 (70.4 ± 14.1 pg/mL), SPIN-2 (86.0 ± 9.3 pg/mL), or cetirizine (112.8 ± 19.3 pg/mL). More importantly, compared with the cetirizine group (1 day), the SPIN-1 or SPIN-2 group shows long-term therapeutic effects (1 week). The SPIN web technique shows the great potential for blocking IgE binding to mast cells in vivo, attenuating AR or other allergic reactions.

Biodegradable Mesoporous Organosilica-Based Nanostabilizer Targeting Mast Cells for Long-Term Treatment of Allergic Diseases

“…The schematic illustration of the AR mice model development and administration is shown in Figure a . To evaluate the therapeutic efficacy of AR treatment, the exhibited number of nasal rubbing and sneezing behaviors were recorded for a duration of 30 min following the 1 h administration of various treatment groups on days 23, 24, 26, 28, 30, 32, and 33.…”

“…The model establishment and treatment process were conducted according to the previous reports . Sensitize: For the initial 14 days period, mice in AR and Se MSNs@CS@Ap groups were intraperitoneally injected with OVA solution (dissolved in Rehydragel@LV Alum Adjuvant, 200 μg/mL, 100 μL) every other day, while the control group received injections of normal saline.…”

“…The schematic illustration of the AR mice model development and administration is shown in Figure 5a. 70 To evaluate the therapeutic efficacy of AR treatment, the exhibited number of nasal rubbing and sneezing behaviors were recorded for a duration of 30 min following the 1 h administration of various treatment groups on days 23, 24, 26, 28, 30, 32, and 33. Based on the biobehavioral scoring criteria, a score higher than 5 in the AR group indicates successful modeling. 71 Obviously, there was a significant reduction in nasal rubbing and sneezing times among mice treated with Se MSNs@CS@Ap during the recorded days (Figure 5b−e).…”

“…The model establishment and treatment process were conducted according to the previous reports. 70 Sensitize: For the initial 14 days period, mice in AR and Se MSNs@CS@Ap groups were intraperitoneally injected with OVA solution (dissolved in Rehydragel@ LV Alum Adjuvant, 200 μg/mL, 100 μL) every other day, while the control group received injections of normal saline. Treat: During days 15−23, 1 h before the Challenge step, the treatment group was daily intraperitoneal injected with Se MSNs@CS@Ap (100 μg/mL, 20 μL), whereas the AR and control groups received equivalent volumes of normal saline.…”

“Live” Nanomaterials Process Biomimetic Recognition and Assembly In Vivo

“…Biomimetic FN/LN peptides could bind specific receptors and form stable NFs through BIF, showing better enzymatic stability. [ 96,97 ] Biomimetic FN/LN peptides may perform natural functions, such as migration inhibition of endothelial cells, as well as other functions, such as embolization of blood vessel, suggesting wide applications of biomimetic ECM. The BIF behavior of FN/LN biomimetic peptides could be achieved through binding many other receptors on cell membranes, which may result in therapeutic agents for various diseases.…”